Scholarlink

Background <p><i>Acinetobacter baumannii</i>, is a WHO-recognized critical pathogen, poses a severe clinical threat due to multidrug resistance, environmental persistence and a robust biofilm formation. The rapid failure of conventional antibiotics necessitates alternative strategies, with bacteriophage therapy emerging as a promising, targeted, and eco-friendly approach.</p> Methods and results <p>In this study, a lytic bacteriophage, designated TANUVAS_MVC-VPH-AB, was isolated and characterized for its activity against <i>Acinetobacter</i> spp. Morphological and genomic analyses classified the phage within the class <i>Caudoviricetes</i>, possessing a linear double-stranded DNA genome of 45&#xa0;kb and a GC content of 37.61%. Genome annotation identified 93 putative genes, with no virulence-associated genes and antibiotic resistance determinants supporting its safety as a potential therapeutic agent. The phage demonstrated strong lytic activity and a restricted yet polyvalent host range within the <i>A. calcoaceticus - A. baumannii</i> complex, along with detectable stability across the tested pH and temperature conditions. Additionally, it demonstrated potent biofilm inhibition and eradication on abiotic surfaces (polystyrene).</p> Conclusion <p>These findings suggest that TANUVAS_MVC-VPH-AB is a promising candidate for bacteriophage therapy, offering a viable alternative to combat MDR <i>A. baumannii</i> infections, particularly in biofilm-associated environments within hospital and food related settings.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Isolation, characterization and genomic insights of the lytic bacteriophage TANUVAS_MVC-VPH-AB targeting Acinetobacter spp. with antibacterial and anti-biofilm activity

  • 期刊论文

  • 发表日期：

    2026年4月2日

查看全文
  • J. Karthikeyan,
  • Porteen Kannan,
  • Sureshkannan Sundaram,
  • S. Rajalakshmi,
  • S. Anbazhagan,
  • Wilfred Ruban Savariraj,
  • P. Nidhi Sudhakaran,
  • P. Dhanalakshmi,
  • M. Nithya Quintoil,
  • R. Sivachandiran,
  • Navya Sri Bairi,
  • Raghavendra G. Amachawadi

摘要

Background

Acinetobacter baumannii, is a WHO-recognized critical pathogen, poses a severe clinical threat due to multidrug resistance, environmental persistence and a robust biofilm formation. The rapid failure of conventional antibiotics necessitates alternative strategies, with bacteriophage therapy emerging as a promising, targeted, and eco-friendly approach.

Methods and results

In this study, a lytic bacteriophage, designated TANUVAS_MVC-VPH-AB, was isolated and characterized for its activity against Acinetobacter spp. Morphological and genomic analyses classified the phage within the class Caudoviricetes, possessing a linear double-stranded DNA genome of 45 kb and a GC content of 37.61%. Genome annotation identified 93 putative genes, with no virulence-associated genes and antibiotic resistance determinants supporting its safety as a potential therapeutic agent. The phage demonstrated strong lytic activity and a restricted yet polyvalent host range within the A. calcoaceticus - A. baumannii complex, along with detectable stability across the tested pH and temperature conditions. Additionally, it demonstrated potent biofilm inhibition and eradication on abiotic surfaces (polystyrene).

Conclusion

These findings suggest that TANUVAS_MVC-VPH-AB is a promising candidate for bacteriophage therapy, offering a viable alternative to combat MDR A. baumannii infections, particularly in biofilm-associated environments within hospital and food related settings.